Many companies, particularly new entrants into the U.S. pharma arena, are facing some level of disruption or impact on their projected timelines for seeking FDA licensure, gathering data from trials for filing, conducting health economics analyses needed to demonstrate improved outcomes, or conducting real-world evidence studies that can help inform medical societies’ deliberations on clinical […]
Category: HEOR/Real World Evidence
Ensuring an Open Channel with Regulatory and Medical Policy Opinion Leaders During COVID
Assessing and managing issues around clinical trials: a multi-stakeholder approach
Many companies are facing challenging decisions on whether to proceed with clinical trials in the coming months as countries experience varying degrees of lockdown.
Unlocking virtual medical congresses
Medical congresses – crucial for the presentation of trial data, scientific exchange and the opportunity to engage with medical professionals, patient advocates, media and analysts – have been cancelled, postponed or are moving to virtual/part virtual.
COVID-19 brings real-world evidence center stage
Now, as we adjust to the era of COVID-19, RWE, and thus real-world research (RWR), has been pushed center stage, and industry, and the medical community as a whole, are turning to this research area for answers.